Tunlametinib

Tunlametinib
Clinical data
Other names	HL-085
ATC code	L01EE06 (WHO) ;
Legal status
Legal status	Rx in China;
Identifiers
	IUPAC name 4-Fluoro-5-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,3-benzothiazole-6-carboxamide;
CAS Number	1801756-06-8;
PubChem CID	71621329;
ChemSpider	115006753;
UNII	IF25NR1PV3;
KEGG	D13236;
ChEMBL	ChEMBL5095241;
Chemical and physical data
Formula	C16H12F2IN3O3S
Molar mass	491.25 g·mol−1

Other namesHL-085

ATC code

L01EE06 (WHO)

Legal status

Rx in China

CAS Number

1801756-06-8

Tunlametinib is a pharmaceutical drug for the treatment of cancer. It is an inhibitor of mitogen-activated protein kinase kinase.^[1]

In China, tunlametinib was approved in 2024 for the treatment of patients with NRAS-mutated advanced melanoma who were previously treated with a PD-1/PD-L1 targeting agent.^[2]^[3]

It is also being studied for use in combination with vemurafenib in patients with advanced BRAF V600-mutant solid tumors.^[4]

[1]

[2]

[3]

[4]

Related Articles